Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHKS94)

• Drug Name: Valaciclovir Drug Info
• Synonyms: Talavir; VACV; ValACV; Valacyclovir; Virval; Zelitrex; Valaciclovir Hcl; Valacyclover Hydrochloric; Valacyclover Hydrochloride; BW256U87; TBB067866; Acyclovir-valine; BW-256U; Valaciclovir (INN); Valaciclovir [INN:BAN]; Valaciclovir, Valtrex; Valtrex (TN); Zelitrex (TN); Valacyclovir, (L)-isomer; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9 H-purin-9-yl)methoxy]ethyl ester, monohydrochloride; 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate

Indication

Disease Entry	ICD 11	Status	REF
Virus infection	1A24-1D9Z	Approved	[1] , [2]

• Therapeutic Class: Antiviral Agents
• Cross-matching ID:
  PubChem CID: 135398742
  ChEBI ID: CHEBI:35854
  CAS Number: CAS 124832-26-4
  TTD Drug ID: DMHKS94
  VARIDT Drug ID: DR00078
  ACDINA Drug ID: D00714

Molecule-Related Drug Atlas

Drug(s) Transported By Peptide transporter 1 (SLC15A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Bacterial infection	1A00-1C4Z	Approved	[7]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[8]
Ampicillin	DMHWE7P	Bacterial infection	1A00-1C4Z	Approved	[9]
Losartan	DM72JXH	Hypertension	BA00-BA04	Approved	[10]
Enalapril	DMNFUZR	Hypertension	BA00-BA04	Approved	[11]
Cefazolin	DMPDYFR	Bacterial infection	1A00-1C4Z	Approved	[12]
Ceftriaxone	DMCEW64	Bacterial infection	1A00-1C4Z	Approved	[13]
Dexamethasone	DMMWZET	Rheumatoid arthritis	FA20	Approved	[8]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[10]
Irbesartan	DMTP1DC	Hypertension	BA00-BA04	Approved	[10]

Drug(s) Transported By Peptide transporter 2 (SLC15A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Bacterial infection	1A00-1C4Z	Approved	[7]
Ampicillin	DMHWE7P	Bacterial infection	1A00-1C4Z	Approved	[14]
Enalapril	DMNFUZR	Hypertension	BA00-BA04	Approved	[15]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[16]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[17]
Cephalexin	DMD5JU8	Bacterial infection	1A00-1C4Z	Approved	[14]
Cefaclor	DMJXDGC	Bacterial infection	1A00-1C4Z	Approved	[7]
Aminolevulinic acid hci	DMS4BLQ	Acne vulgaris	ED80	Approved	[18]
Spirapril	DM5XLTY	Hypertension	BA00-BA04	Approved	[19]
Cefixime	DMY60I8	Bacterial infection	1A00-1C4Z	Approved	[14]

Drug(s) Transported By Organic anion transporter 3 (SLC22A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[20]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[21]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[6]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[22]
Pravastatin	DM6A0X7	Hypercholesterolaemia	5C80.0	Approved	[23]
L-tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[24]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Pitavastatin calcium	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[26]
Rosuvastatin	DMMIQ7G	Hypercholesterolaemia	5C80.0	Approved	[27]
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[28]

Drug(s) Transported By Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Virus infection	1A24-1D9Z	Approved	[29]
Ganciclovir	DM1MBYQ	Virus infection	1A24-1D9Z	Approved	[29]
Levacecarnine HCL	DMJBOCR	Cognitive impairment	6D71	Approved	[30]
Glycine	DMIOZ29	Malnutrition	5B50-5B71	Approved	[31]
L-glutamine	DM69G8X	Short bowel syndrome	KB89.1	Approved	[32]
Valganciclovir	DMS2IUH	Virus infection	1A24-1D9Z	Approved	[33]
Nitric Oxide	DM1RBYG	Respiratory failure	CB41	Approved	[34]
D-Serine	DM3YH4I	N. A.	N. A.	Phase 4	[35]
L-threonine	DMFHTBX	Discovery agent	N.A.	Investigative	[35]

Drug(s) Targeting Herpes simplex virus DNA polymerase UL30 (HSV UL30)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[36]
Aciclovir	DMYLOVR	Virus infection	1A24-1D9Z	Approved	[37]
Ganciclovir	DM1MBYQ	Virus infection	1A24-1D9Z	Approved	[38]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[37]
Valganciclovir	DMS2IUH	Virus infection	1A24-1D9Z	Approved	[39]
Penciclovir	DMOUMDV	Human immunodeficiency virus infection	1C62	Approved	[40]
Famciclovir	DMJHLSD	Virus infection	1A24-1D9Z	Approved	[41]
Valacyclovir Hydrochloride	DM5I1CE	Herpes simplex virus infection	1F00	Approved	[37]
Foscavir	DM9KJLZ	Cytomegalovirus retinitis	9B72.00	Approved	[39]
Netivudine	DMTKRY1	Virus infection	1A24-1D9Z	Phase 3	[42]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Herpes simplex virus DNA polymerase UL30 (HSV UL30)	TTIU7X1	DPOL_HHV11	Inhibitor	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)	DTW7AE3	AAAT_HUMAN	Substrate	[4]
Peptide transporter 2 (SLC15A2)	DT8QKNP	S15A2_HUMAN	Substrate	[5]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[5]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4824).
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15.
• [4] Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47.
• [5] Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
• [6] Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
• [7] Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
• [8] Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
• [9] Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
• [10] High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
• [11] The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
• [12] Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
• [13] Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
• [14] Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
• [15] Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
• [16] The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
• [17] Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
• [18] PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
• [19] Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
• [20] Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
• [21] Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
• [22] Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
• [23] Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
• [24] Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
• [25] Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
• [26] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [27] The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
• [28] Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
• [29] Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
• [30] A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70.
• [31] Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1046-53.
• [32] High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
• [33] Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
• [34] Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.
• [35] D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
• [36] Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.
• [37] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [38] Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81.
• [39] Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
• [40] Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66.
• [41] Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8.
• [42] Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999 Feb;57(2):187-206.